Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
May 05, 2022 11:55 ET
|
Zai Lab Limited
- Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316); responders observed across patient types...
Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
April 28, 2022 07:30 ET
|
Zai Lab Limited
91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1) In the TKI-naïve China subpopulation by BICR, the...
Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm
April 21, 2022 07:30 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab to Announce First Quarter 2022 Financial Results on May 10, 2022
April 20, 2022 07:30 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Plants a Tree for Every Employee on Earth Day 2022
April 19, 2022 08:00 ET
|
Zai Lab Limited
SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting
April 06, 2022 08:01 ET
|
Zai Lab Limited
- First preview of preclinical data for ZL-1218, an anti-CCR8 antibody, in an oral presentation - Poster presentations will feature three additional candidates of Zai Lab’s internal...
Zai Lab Announces Change to Virtual Extraordinary General Meeting of Shareholders to be Held on March 28, 2022
March 23, 2022 07:30 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO, and CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology Meeting
March 20, 2022 20:00 ET
|
Zai Lab Limited
PRIME study demonstrates that niraparib treatment had a statistically significant and clinically meaningful improvement in progression-free survival in the overall study population regardless of...
Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer
March 15, 2022 07:30 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021
March 01, 2022 16:05 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...